license out
-
Licensing of Serum Group B Meningococcal Vaccine (China Region) | DrugTimes BD Project
Please contact DrugTimes BD Team at BD@drugtimes.cn
-
How Do American and European Biotech Companies Make Money Using Chinese New Drugs? Sharing Successful Cases of LIDLO, LIDMA, and LIDIPO
Welcome friends to share your views in the comments section! DrugTimes will continue to pay close attention and follow up on the reports
-
【Urgent Request】European and American biotech companies are interested in licensing drugs for PD, AD and other CNS diseases
If interested in this licensing opportunity, please contact DrugTimes BD Team at BD@drugtimes.cn
-
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Congratulations to Day One Biopharmaceuticals and MabCare Therapeutics!
-
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases
Congratulations to Roche and Ascidian Therapeutics!
-
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Congratulations! This is the latest cross-border licensing out deal by a pharma/biotech in China
-
TOP10 MNC Seeking FIC or BIC Products: IPF
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line
-
TOP10 MNC Seeking FIC or BIC Products: COPD
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line
-
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
If you are looking for a promising TL1A product, please contact DrugTimes BD Team (BD@drugtimes.cn)
-
药时代BD项目 | 寻找非肿瘤药项目，各个阶段，各种权益均感兴趣
项目编号：DT-BD-20200412-012
